American Board of Internal Medicine (ABIM) Certification Practice Exam

Which three anti-TNF antibodies are approved for ulcerative colitis?

1. Adalimumab, vedolizumab, infliximab

2. Infliximab, adalimumab, golimumab

3. Golimumab, certolizumab, infliximab

4. Ustekinumab, infliximab, golimumab

The correct answer is: Infliximab, adalimumab, golimumab

The three anti-TNF antibodies that are specifically approved for the treatment of ulcerative colitis are infliximab, adalimumab, and golimumab. Infliximab was one of the first medications approved for ulcerative colitis and is a chimeric monoclonal antibody that targets TNF-alpha, which plays a crucial role in the inflammatory process of the disease. It is administered via intravenous infusion and has been shown to induce and maintain remission in patients with moderate to severe ulcerative colitis. Adalimumab is a fully human monoclonal antibody against TNF-alpha, available for subcutaneous injection. It provides an important option for patients who may prefer or require an at-home injectable medication. It has shown effectiveness in treating both adult and pediatric populations with ulcerative colitis. Golimumab is also a fully human anti-TNF monoclonal antibody approved for ulcerative colitis. It is given as a subcutaneous injection after an initial loading dose, and it works similarly to the other two by inhibiting TNF-alpha, reducing inflammation and symptoms of the disease. The other options do not contain the correct combination of anti-TNF antibodies approved for ulcerative colitis. For example, vedoliz